TABLE 1:
DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF STUDY PARTICIPANTS.
| Variable | Total N=132 | |
|---|---|---|
| Women, n (%) | 89 (67.4) | |
| Age (years), Median (IQR) | 32(27–41) | |
| Body mass index (BMI)1 Median (IQR) | 24.6 (21.5–28.0) | |
| Experienced | 68 (51.5) | |
| ART regimen | ||
| TDF based | 71 (75.5) | |
| Non-TDF based | 23 (24.5) | |
| Duration on ART (months) Median (IQR) | 5.1 (0–34.6) | |
| 1 | 54 (40.9) | |
| 2 | 42 (31.8) | |
| 3 | 30 (22.7) | |
| 4 | 6 (4.6) | |
| CD4 Overall3 Median (IQR) | 426 (261–583) | |
| HIV viral load log10 (copies/mL)4 | 3.71 (3.46–3.98) | |
| <34 (undetectable) | 64 (48.5) | |
| Education (%) | ||
| Pre-primary and Primary | 46 (34.8) | |
| Post primary | 86 (65.2) | |
| 0–3 | 66 (50.4) | |
| ≥4 | 65 (49.6) | |
| Yes | 12 (9.1) | |
| Yes | 21 (15.9) | |
| Yes | 31 (23.5) | |
| Never | 116 (87.9) | |
| Current | 2 (1.5) | |
| Past | 14 (10.6) | |
TDF= tenofovir, 3TC= lamivudine, EFV= efavirenz, NVP=Nevirapine, AZT= Zidovudine, LPVr=boosted lopinavir,
1
missing data for 4 participants,
2
ART naïve definition <3/12 on ART,
3
missing CD4 results in 24,
4
geometric mean computation didn’t factor in the 64/132 whose HIV viral load was undetectable.
5
missing data in 1 participant